Regulators: Reckitt's K-Y buy could hurt price competition; Zerbaxa labels causing dosage confusion;

@FiercePharma: Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article | Follow @FiercePharma

@EricPFierce: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of  0.9% sodium chloride. More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday - Report: Cadila next in line for injectables bulk-up as it nears deal for Claris. Story | Follow @CarlyHFierce

> U.K. regulators have raised concerns that Reckitt Benckiser's planned acquisition of the K-Y brand of personal lubricants from Johnson & Johnson could lead to higher prices. Report

> The FDA says it's warning healthcare professionals that the labels of Merck's ($MRK) Zerbaxa cause confusion over dosages. Report

> GW Pharmaceuticals ($GWPH) has appointed Julian Gangolli as president of its North American division and is relocating its CEO Justin Gover to the U.S. More

> Kirkland & Ellis, the law firm advising Teva ($TEVA)on its Mylan ($MYL) bid, has hit back at Mylan's attempt to disqualify it from doing so, calling the company's effort an antitakeover tactic. More (sub. req.)

Medical Device News

@FierceMedDev: Neuwave Medical reels in $25M for minimally invasive ablation device. Story | Follow @FierceMedDev

@VarunSaxena2: Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say $STJ. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT CEO Omar Ishrak on the company's strategy in #India: Article | Follow @EmilyWFierce

> India developing federal medical device surveillance system. News

> Report: Researchers develop neuron chips to direct movement of robotic prosthetics. More

Biotech News

@FierceBiotech: Amgen's PCSK9 contender lines up for first place in the blockbuster EU race. Story | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> Novartis' duo of COPD drugs clears Phase III on the path to an FDA decision. More

> Otonomy's ear disease drug slips in Phase IIb, but management keeps the faith. Article

And Finally... Roche's ($RHHBY) Genentech has unveiled an eco-friendly 255,000-square-foot office structure, complete with sun-blocking fins that look like DNA. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.